Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross-sectional multicentre study
|
|
- Cuthbert Garrison
- 5 years ago
- Views:
Transcription
1 ORIGINAL PAPER Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross-sectional multicentre study J. L. Corhay, 1 W. Vincken, 2 M. Schlesser, 3 P. Bossuyt, 4 J. Imschoot 4 Linked Comment: Burgel. Int J Clin Pract 2013; 67: Respiratory Department, Centre HospitalierUniversitaire du Sart-Tilman, Liege, Belgium 2 Respiratory Department, Universitair Ziekenhuis Brussel, Brussels, Belgium 3 Respiratory Department, Centre Hospitalier du Luxembourg, Luxembourg, Luxembourg 4 Medical Department, Takeda Belgium, Brussels, Belgium Correspondence to: Jean L. Corhay, Department of Pneumology, CHU Sart-Tilman B-35, Liege 4000, Belgium Tel.: Fax: jlcorhay@chu.ulg.ac.be Disclosures Jean L. Corhay has received consultancy honoraria from AstraZeneca, Boehringer Ingelheim/Pfizer, GlaxoSmithKline, Novartis and Takeda. Walter Vincken received consultancy honoraria from AstraZeneca, Boehringer Ingelheim/Pfizer, GlaxoSmithKline, Novartis, Mundipharma, MEDA and Takeda. Pascale Bossuyt and Johan Imschoot are employees of Takeda Belgium. SUMMARY Background and aims: Chronic bronchitis (CB) in chronic obstructive pulmonary disease (COPD) patients is associated with increased mortality, frequent exacerbations and faster disease progression. This study investigates the prevalence of CB in a large population of COPD patients to identify features associated with CB. Methods: Cross-sectional multicentre study in patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 2 4 from Belgium and Luxembourg. Results: The 974 patients included were on average years old; 72% were male, FEV 1 was % of predicted. The prevalence of CB was 64% (622/974). In patients with CB, the number of pack-years smoked and the prevalence of chronic respiratory failure, cachexia and skeletal muscle wasting were significantly higher, whereas FEV 1 and FEV 1 /VC were lower. The prevalence of CB increased with GOLD stage and was higher in patients with emphysema and those exposed to occupational risk factors. The CB group had more exacerbations, a higher percentage of patients with frequent exacerbations (37.3% vs. 14.2% of patients; p < ), increased COPD-related, non-intensive care unit hospitalisations and all-cause hospitalisation rates. In multiple logistic regression analysis, frequent exacerbation was the most important independent variable associated with CB, followed by current smoking, chronic respiratory failure, COPD duration and age. Conclusions: CB prevalence in GOLD stage 2 4 COPD patients is high. CB is related to current tobacco smoking, and prevalence increases with COPD severity and duration, emphysema and age. CB could be the hallmark of a subtype of COPD easy to identify in clinical practice, associated with increased disease severity and increased risk of exacerbation. Introduction What s known Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease with variable clinical presentation. Chronic bronchitis is present in a considerable percentage of COPD patients, but prevalence figures reported vary widely. What s new The present study analyses the prevalence of chronic bronchitis and its association with disease and patient characteristics in a cross-sectional multicentre study in a large population of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2 4 COPD patients. Chronic bronchitis could be the hallmark of a subtype of COPD associated with increased disease severity and increased risk of exacerbation. Chronic obstructive pulmonary disease (COPD) is a major health problem and a leading cause of morbidity and mortality in the adult population worldwide. Increasing evidence indicates that COPD is a heterogeneous disease (1) and that different subtypes or phenotypes may contribute to a variable extent to the severity of the disease. Chronic bronchitis (CB) is a clinically and epidemiologically useful entity, defined as the presence of cough and sputum production for at least 3 months in each of 2 consecutive years. Chronic cough and sputum production are symptoms of mucus hypersecretion in proximal airways. CB is a well-known feature present in a considerable percentage of COPD patients, although it was not included in the definition of COPD in any version of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report (2). Chronic bronchitis is considered a major manifestation of COPD, but the prevalence of CB in COPD varies widely. Lower prevalence was found in populationbased studies (14 30%) (3,4) and higher prevalence in clinical-based studies ( %) (1,5 10). It is suggested that CB is not an innocent manifestation in patients with COPD, as epidemiologic studies observed that CB in COPD patients is associated with increased mortality (11 13), frequent exacerbations including those requiring hospitalisation (4,7,9,10), worse respiratory symptoms (4,7), disease progression (14), physical activity limitation (4), and worse general health status (1,4,7). However, in the large observational evaluation of COPD longitudin doi: /ijcp.12248
2 Chronic bronchitis in COPD patients 1295 ally to identify predictive surrogate endpoints (ECLIPSE) study, CB was not associated with an accelerated rate of decline in forced expiratory volume in 1 second (FEV 1 ) (8), leaving the impact of CB on the disease course of COPD still controversial, despite some biological evidence of a distinct inflammatory cell profile in the airways of COPD patients with CB (15). CB associated with COPD could be a therapeutic target (16), reminding that early studies that validated inhaled corticoids in COPD selected patients on the presence of symptoms of CB (17,18) and that recent studies validated phosphodiesterase-4 inhibitor in preventing the development of exacerbation in COPD patients with CB (2). To address the uncertainty regarding the prevalence of CB in COPD patients, we analysed the prevalence of CB and its association with different disease and patient characteristics in a large population of GOLD stage 2 4 COPD patients from Belgium and Luxembourg. Methods Population and study design In this cross-sectional multicentre study, we investigated the prevalence of CB and its association with disease and patient characteristics, exacerbations and COPD treatment in ambulant patients with moderate-to-severe COPD. Between October 2010 and April 2011, pneumologists from 16 pneumology departments in Belgium and Luxembourg (8 from the Flemish and 7 from the French speaking part of Belgium, 1 from Luxembourg) enrolled consecutive COPD outpatients fulfilling the study s eligibility criteria. To be eligible, patients had to present with COPD of stages 2 4 according to the GOLD diagnostic criteria (2). The study protocol was approved by the ethics committee of Liege (B ) which acted as the central ethics committee for Belgium, and by the local ethics committees of all participating centres. Written informed consent was obtained from all patients prior to or at inclusion. Data collection Data were collected using a structured questionnaire available in Dutch, French and German (Online supplemental Material/Appendix) in a single outpatient visit. The standardised questionnaire covered demographic data, COPD characteristics (duration, severity, presence of CB and emphysema), spirometric data, presence of pulmonary risk factors and comorbidities, exacerbations and hospitalisations over the last 12 months, and current COPD maintenance treatment. Demographic data included age, gender, height and weight. Severity of pulmonary obstruction was assessed using the GOLD staging criteria (2). Spirometric data comprised postbronchodilator FEV 1 (% predicted and absolute values) and postbronchodilator FEV 1 /VC (vital capacity, %). If available, data of three spirometric evaluations were collected; the most recent spirometry and spirometric evaluations performed about 6 months (interval of 4 8 months) and 12 months (interval of months) before inclusion. The presence of emphysema was appreciated by the chest physician and radiologist, and based on their interpretation of CT scan of the thorax and/or on transfer factor of lung for carbon monoxide (TLCO) measurement. Chronic bronchitis was defined as cough and sputum production for at least 3 months in each of two consecutive years, in the absence of other causes of chronic cough (19). Smoking history included smoking status and number of pack-years. To investigate occupational risk factors, the exposure to mineral, organic or metallic dusts, fumes and vapours was assessed. The number and severity of exacerbations over the last 12 months was recorded. Exacerbations were graded as mild when the increased severity of respiratory symptoms could be controlled by the patient with an increase in the usual medication, as moderate when requiring treatment with systemic corticosteroids and/or antibiotics and as severe if hospitalisation or a visit to the emergency department was required. The number of exacerbations was determined according to the patient s self-reported events (for mild and moderate exacerbations), and as noted in the medical file (for moderate and severe exacerbations). Additionally, the number of COPDrelated visits to the emergency department, visits to the emergency department without hospitalisation, COPD-related hospitalisation with or without stay in the intensive care unit and the overall number of hospitalisations (including those because of COPD) over the last year were recorded. Comorbidities were diagnosed by the chest physician according to personal clinical judgement and/or recorded from the data file of the patient. Comorbidities recorded included respiratory diseases (allergy, asthma and chronic respiratory failure), cardiovascular diseases (ischaemic heart disease, heart failure and hypertension), osteoporosis, skeletal muscle wasting, cachexia, diabetes mellitus, depression, anaemia, gastroesophageal reflux disease and lung cancer. The COPD treatment parameters comprised current COPD treatment as well as long-term oxygen therapy, influenza vaccination and smoking cessation therapy over the last 12 months.
3 1296 Chronic bronchitis in COPD patients Determination of sample size As the reported prevalence of CB in COPD patients varies between 50% and 80%, a study population of approximately 1000 COPD patients is needed in order to have at least 251 patients in the group without CB. A sample size of 251 patients per group is necessary for a two-sided statistical test to detect a difference of 0.25 exacerbations/patient/year between patients with and without CB with at least 95% power, at a significance level of alpha = 0.05 and with an assumed common standard deviation of 1.0. An earlier study performed in France by Burgel et al. (10) with a similar design and end-points compared patients with and without CB in a cohort of 433 subjects. With a sample size of about 1000 patients it would be possible to identify additional features associated with CB in COPD patients. Statistical analysis Patients were only included in the statistical analysis if the following minimal data were available: gender and age; GOLD stage; presence or absence of CB; number and severity of exacerbations over the last 12 months. Quantitative variables are reported as the mean standard deviation or median (5th and 95th percentiles); categorical variables are presented as percentages. Percentages are based on the total number of patients in the analysis set, i.e. missing values are also tabulated including percentages unless otherwise specified. Number and percentage of missing observations are provided for all parameters. Differences between patients with and without CB were analysed using Fisher s exact test or the v 2 test for binary variables, Mann Whitney U-test for ordinal variables, and unpaired t-tests for normally distributed variables. CB prevalence was calculated using the normal approximation and presented as point estimate with the corresponding two-sided 95% confidence interval. All variables associated with the CB subtype with a p < 0.10 in univariate analysis were included in a multivariate logistic regression model to identify variables independently associated with CB. Statistical analysis was performed with Microsoft Excel version 2007 and Medcalc version software (MedCalc Software, Mariakerke, Belgium). A p-value of 0.05 was considered statistically significant. Results Population characteristics and prevalence of chronic bronchitis Data from 976 subjects were collected, 625 from the Flemish part and 311 patients from the French part of Belgium, and 38 patients from Luxembourg. Two patients were excluded from the analysis because the minimal criteria for analysis were not met. Thus, data analysis was performed for 974 subjects. The characteristics of the study population are summarised in Table 1. Patients in this study were on average years old, 72% were male and mean FEV 1 was % of predicted. The prevalence of CB was 64% (CB present in 622/974 patients). Comparison of COPD patients with and without chronic bronchitis No significant difference was observed between patients with and without CB for age, gender, smoking status, body mass index (BMI) (Table 1) and prevalence of most comorbidities (asthma, allergy, cardiovascular disease, osteoporosis, anaemia, lung cancer, depression and diabetes) (Table 2). Chronic respiratory failure, cachexia and skeletal muscle wasting, however, were more frequently present in the group with CB. The number of pack-years and COPD duration were higher, and both FEV 1 % predicted and FEV 1 /VC% were lower in patients with CB. The proportion of patients with CB increased with GOLD stage (Figure 1) and the prevalence of CB was higher in patients with emphysema and in patients exposed to occupational risk factors. Chronic bronchitis and COPD exacerbations The overall number of exacerbations per patient per year was significantly higher in patients with CB ( vs ; p < 0.001), as were the numbers of mild ( vs ; p = 0.002), moderate ( vs ; p < ) and severe ( vs ; p = ) exacerbations per patient per year (Table 3). The percentage of patients with frequent (moderate or severe) exacerbations (defined as two or more per patient per year) was higher in the CB group than in the group without CB (37.3% vs. 14.2% of patients; p < ). The percentage of patients who experienced mild, moderate or severe exacerbations over the last year was higher in the CB group (Figure 2). More hospitalisations and more COPD-related hospitalisations without stay at the intensive care unit were observed for COPD patients with CB (Table 4). COPD treatment in patients with and without chronic bronchitis Chronic obstructive pulmonary disease patients with CB are treated more often with theophyllines, antibiotics and smoking cessation therapy, but less frequently used long-acting muscarinic antagonist (LAMA) monotherapy than COPD patients without
4 Chronic bronchitis in COPD patients 1297 Table 1 Population characteristics and comparison of chronic obstructive pulmonary disease patients with (CB+) and without (CB ) chronic bronchitis Total CB+ CB N = 974 N = 622 N = 352 p-value Age (years) * Gender (% female) Disease duration (years) * FEV1 (% predicted) <0.0001* FEV1/VC (%) * Smoking status, % (n) Never smoked 5.85 (57) 4.98 (31) 7.39 (26) Former smoker (645) (398) (247) Current smoker (271) (192) (79) Unknown 0.10 (1) 0.16 (1) 0.00 (0) Number of pack years, % (n) <10 years 1.97 (18) 1.53 (9) 2.76 (9) 0.043* years 8.52 (78) 8.64 (51) 8.28 (27) >20 years (811) (524) (287) Unknown 0.98 (9) 1.02 (6) 0.92 (3) Body mass index (kg/m²) Emphysema, % (n) Present (589) (403) (186) <0.0001* Absent (371) (206) (165) Unknown 1.44 (14) 2.09 (13) 0.28 (1) Occupational risk factors, % (n) Present (396) (259) (137) 0.025* Absent (575) (361) (214) Unknown 0.31 (3) 0.32 (2) 0.28 (1) *p < Postbronchodilator. Refers to current and former smokers only. Patients were considered to have chronic bronchitis (CB+) if they noted chronic cough and phlegm production for 3 month/year over two consecutive years. CB, chronic bronchitis; FEV 1, forced expiratory volume in 1 second; VC, vital capacity. CB (Table 5). The percentage of COPD patients treated with systemic corticoids tended to be higher in the CB group, but this trend did not reach statistical significance. Identification of variables independently associated with chronic bronchitis In a multiple logistic regression analysis, we found that frequent exacerbation was the most important independent variable associated with CB, followed by current smoking. Other variables significantly associated with CB were chronic respiratory failure, duration of COPD and age (Table 6). Gender, BMI, allergy, asthma, GOLD stage and comorbidities were tested but not included in the logistic regression model. Discussion This observational study in a large population of COPD patients found that the prevalence of CB in COPD patients is high (64%) and increases with the severity of obstruction. In our study, the presence of CB was associated with risk factors such as smoking status, duration of COPD, age, and also with features such as chronic respiratory failure and a history of frequent (moderate or severe) COPD exacerbations. Among the systemic comorbidities investigated, cachexia and skeletal muscle wasting were more frequent in COPD patients with CB. The prevalence of CB in our study population of COPD patients is higher than that reported in most previous studies (3 9). Differences in the prevalence of CB between studies could result from the definition of CB used as well as from differences between the study populations as suggested recently by Burgel (20). Indeed, we had a selected population of symptomatic patients with moderate to very severe COPD consulting the outpatient pneumology clinic. The mean age and the proportion of current smokers were also high in our COPD cohort. It is well known that the risk of CB increases with age and tobacco consumption (21). In a recent large Danish co-twin
5 1298 Chronic bronchitis in COPD patients Table 2 Presence of concomitant diseases in chronic obstructive pulmonary disease patients with (CB+) and without (CB ) chronic bronchitis CB+ CB N = 622 N = 352 p-value N # Respiratory diseases Allergy 8.9 (55) 12.5 (44) Asthma 10.8 (67) 13.1 (46) Chronic respiratory failure 18.3 (114) 9.4 (33) * 960 Cardiovascular diseases Ischaemic heart disease 22.1 (137) 19.9 (70) Heart failure 13.5 (84) 11.9 (42) Hypertension 39.5 (246) 39.8 (140) Other relevant disease Osteoporosis 17.7 (110) 17.0 (60) Skeletal muscle wasting 22.8 (142) 13.4 (47) * 959 Cachexia 12.7 (79) 6.8 (24) * 964 Diabetes mellitus 12.7 (79) 10.5 (37) Depression 19.1 (119) 14.2 (50) Anaemia 6.4 (40) 5.1 (18) Gastroesophageal reflux 21.2 (132) 19.0 (67) Lung cancer 6.6 (41) 9.4 (33) *p < N #, number of patients with available data; CB, chronic bronchitis. % of Patients 80% 60% 40% 20% 0% CB CB+ p < II III IV GOLD Stages Figure 1 Distribution of global initiative for chronic obstructive lung disease stages and chronic bronchitis in our chronic obstructive pulmonary disease population. CB, chronic bronchitis control analysis, the risk of CB was confirmed to increase among smokers in a dose-dependent manner and in older subjects (22). Moreover, in a French study with the same methodology and a comparable proportion of smokers, the prevalence of CB was similar (74%) (10). We found an increased prevalence of emphysema in our CB subgroup, in contrast to the COPDGene study, where there was no difference in the percentage of patients with emphysema between COPD groups with and without CB (7). This could be explained by the fact that in our study, emphysema was reported retrospectively by the appreciation of chest physician and radiologist based on their interpretation of CT scan of the thorax and/or TLCO, whereas the COPDGene study prospectively assessed Table 3 Chronic obstructive pulmonary disease exacerbations in patients with (CB+) and without chronic bronchitis (CB ) CB+ CB N = 622 N = 352 p-value All <0.001* Mild * Moderate <0.0001* Severe * *p < The number of exacerbations per patient per year is expressed as mean SD. CB, chronic bronchitis. the degree of emphysema by CT scan of the thorax and the measurement of Hounsfields units. We also found that COPD patients with CB had a worse pulmonary function, and that prevalence of CB increased with GOLD stage. These findings are consistent with those reported in both unselected and selected populations of COPD (1,4), although in the COPDGene study, no difference in pulmonary function was observed between COPD groups with or without CB (7). Chronic obstructive pulmonary disease is well known to be associated with systemic manifestations and comorbidities (23). We found that in our COPD patients, among all examined systemic manifestations
6 Chronic bronchitis in COPD patients 1299 Figure 2 Percentage of patients with mild, moderate, severe and frequent exacerbations of chronic obstructive pulmonary disease. Frequent exacerbations: at least two moderate and/or severe exacerbations per year. CB, chronic bronchitis Table 4 Hospitalisations in chronic obstructive pulmonary disease (COPD) patients with (CB+) and without chronic bronchitis (CB ) CB+ CB N = 622 N = 352 p-value N # Hospital visits related to COPD Emergency department without hospitalisation Hospitalisation without stay at ICU * 969 Hospitalisation with stay at ICU All-cause hospitalisations ** 964 *p < 0.01, **p < The number of hospitalisations per patient per year is expressed as mean SD. N #, number of patients with available data; CB, chronic bronchitis; ICU, intensive care unit. and comorbidities, cachexia and skeletal muscle wasting were more frequently encountered in the CB than in the non-cb group. Moreover, hospitalisations not related to COPD were more frequent in the CB group. Of interest is the fact that prevalence of anaemia (5%), a recently recognised comorbidity in COPD (24), is similar between the COPD patients with and without CB. Our study clearly shows that CB in COPD patients is associated with a higher risk of frequent exacerbations, including severe exacerbations requiring hospitalisation. This confirms the findings of Burgel (10) in a French multicentre study including 433 COPD patients. However, in the epidemiological ECLIPSE study, the CB subtype in COPD was not associated with an increase in moderate and severe exacerbations, neither in the year prior to study entry (1) nor during the first year of follow-up (25). Reasons for these discrepancies in association with CB and COPD exacerbations remain to be established. A larger percentage of COPD patients with CB are using oral theophyllines, preventive antibiotics and smoking cessation therapy. This could be explained by the fact that the CB subpopulation has more obstruction and exacerbations, and contains a greater proportion of current smokers. Moreover, the fact that smoking cessation therapy is more frequent in the group of chronic bronchitis could hint to a poorer quality of life (1,4,7) pushing patients to stop smoking. Inhaled therapies did not differ between COPD patients with and without CB, except that those with CB less often used LAMA monotherapy. That is surprising because LAMA is well known to produce benefits on symptoms and exacerbations rates (26). Burgel et al. did not find differences in inhaled treatments between both groups of COPD patients (10). In contrast, in the COPDGene study the CBgroup reported a greater use of short-acting bronchodilators and lesser use of combination inhaled steroid/long-acting b-agonists, but the use of LAMA was similar in both subgroups (7). Additional epidemiological studies focusing on the treatment of COPD are necessary to clarify these differences. We also would like to underline that approximately 75%
7 1300 Chronic bronchitis in COPD patients Table 5 Current chronic obstructive pulmonary disease treatment in patients with (CB+) and without chronic bronchitis (CB ) Total CB+ CB N = 974 N = 622 N = 352 p-value No treatment 1.4 (14) 1.8 (11) 0.9 (3) Inhaled therapy LABA only 6.8 (66) 6.6 (41) 7.1 (25) LAMA only 18.1 (176) 14.5 (90) 24.4 (86) <0.0001* LABA + ICS 75.2 (732) 76.7 (477) (255) LABA + ICS + LAMA 60.1 (585) 58 (361) 63.6 (224) Oral therapies Theophylline 17.5 (187) 22.0 (137) 14.2 (50) 0.003* Corticosteroids 8.3 (81) 9.6 (60) 6 (21) Mucolytics 20.2 (197) 20.0 (124) 20.7 (73) Antibiotics 4.0 (39) 5.6 (35) 1.1 (4) * Other therapies Oxygen 10.5 (102) 10.1 (63) 11.1 (39) Smoking cessation therapy 18.3 (178) 21.5 (134) 12.5 (44) * Influenza vaccination 71.3 (694) 71.7 (446) 70.4 (248) *p < Over the last 12 months. Data are expressed as percentage of patients treated (number of patients). CB, chronic bronchitis; ICS, inhaled corticosteroids; LABA, long-acting b 2 -agonist; LAMA, long-acting muscarinic antagonist. Table 6 Factors associated with the presence of chronic bronchitis in chronic obstructive pulmonary disease (COPD) patients Variable b SE Estimated OR 95% CI p-value Frequent exacerbations < * Current smoker < * Chronic respiratory failure * Duration of COPD * Age (years) * Emphysema *p < Multivariate logistic regression with chronic bronchitis as the dependent variable. Variables included in this model were those associated with chronic bronchitis with p < 0.10 in univariate analysis. b, estimated coefficient; OR, odds ratio; SE, standard error; CI, confidence interval. of patients were receiving ICS in both the CB and the non-cb group. However, ICS is currently recommended in severe COPD (< 50% predicted) and frequent exacerbations. As the lack of chronic bronchitis is associated with clearly less exacerbation, this points to an overuse of ICS in the group without CB. This is important as there is now a clear recognition of side effects of ICS in COPD (namely pneumonia) revealed by recent trials or observational studies (2,27). Several limitations of the present study must be taken into account. First, the allocation of a patient to the CB group is based on the perception of the symptoms by the patient himself, which may be subject to a recall or interpretation bias. Second, data were obtained cross-sectionally, and the number of exacerbations and their severity were determined according to medical files and patient recollections. In particular the data collected from the patients may be incomplete, as Seemungal found that about 50% of acute exacerbations of COPD are not reported by patients (28). Thus, mild exacerbations could be underestimated in the present study. However, moderate and especially severe exacerbations were evaluated objectively based on medical records, and both were more frequent in the CB group.
8 Chronic bronchitis in COPD patients 1301 Finally, our study helps to understand the prevalence of CB in an unselected COPD population and suggest that CB in COPD is possibly associated with worse outcomes. COPD with CB could represent a subtype of COPD that is easy to identify in clinical practice and appears to be associated with increased disease severity and with a high risk of exacerbations. Acknowledgements This research was supported by Takeda. The authors acknowledge the contribution of Veerle Persy (HuginMugin Research) as an independent medical writer for editing and writing assistance, funded by Takeda Belgium. Author contributions Corhay JL, Vincken W, Schlesser M, Bossuyt P and Imschoot J participated in the conception and design of the study, in the acquisition of data, in the analysis and interpretation of data. Corhay JL drafted the article; all authors participated in revising it critically for important intellectual content. All authors gave their final approval on the version to be submitted. References 1 Agusti A, Calverley P, Celli B et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11: From the Global Strategy for the Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD) [Internet] org/ (accessed July 2013). 3 Lu M, Yao W, Zhong N et al. Chronic obstructive pulmonary disease in the absence of chronic bronchitis in China. Respirology 2010; 15: Montes de Oca M, Halbert RJ, Lopez MV et al. The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J 2012; 40: Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164: Marsh SE, Travers J, Weatherall M et al. Proportional classifications of COPD phenotypes. Thorax 2008; 63: Kim V, Han MK, Vance GB et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 2011; 140: Vestbo J, Edwards LD, Scanlon PD et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: Miravitlles M, Guerrero T, Mayordomo C, Sanchez-Agudo L, Nicolau F, Segu JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000; 67: Burgel P-R, Nesme-Meyer P, Chanez P et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8: Pelkonen M, Notkola I-L, Nissinen A, Tukiainen H, Koskela H. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006; 130: Ekberg-Aronsson M, Pehrsson K, Nilsson J-A, Nilsson PM, L ofdahl C-G. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005;6: Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: Snoeck-Stroband JB, Lapperre TS, Gosman MME et al. Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Eur Respir J 2008; 31: Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: Dompeling E, Van Schayck CP, Molema J, Folgering H, Van Grunsven PM, Van Weel C. Inhaled beclomethasone improves the course of asthma and COPD. Eur Respir J 1992; 5: Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152(5 Pt 2): S Burgel P-R. Chronic cough and sputum production: a clinical COPD phenotype? Eur Respir J 2012; 40: Montnemery P, Adelroth E, Heuman K et al. Prevalence of obstructive lung diseases and respiratory symptoms in southern Sweden. Respir Med 1998; 92: Meteran H, Thomsen SF, Harmsen L, Kyvik KO, Skytthe A, Backer V. Risk of chronic bronchitis in twin pairs discordant for smoking. Lung 2012; 190: Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: Portillo K, Martinez-Rivera C, Ruiz-Manzano J. Anaemia in chronic obstructive pulmonary disease. Does it really matter? Int J Clin Pract 2013; 67: Hurst JR, Vestbo J, Anzueto A et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9:CD doi: / CD pub2. 28 Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157(5 Pt 1): Paper received May 2013, accepted July 2013
Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationTitle: Objective measurement of cough frequency during COPD exacerbation convalescence
The final publication is available at Springer via http://dx.doi.org/10.1007/s00408-015-9782-y Title: Objective measurement of cough frequency during COPD exacerbation convalescence Michael G Crooks 1,
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationChronic bronchitis has been defined as. The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study
Eur Respir J 2012; 40: 28 36 DOI: 10.1183/09031936.00141611 CopyrightßERS 2012 The chronic phenotype in subjects with and without COPD: the PLATINO study Maria Montes de Oca*, Ronald J. Halbert #, Maria
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationTo describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype.
Educational aims To describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype. To describe the spectrum of pharmacological and non-pharmacological interventions
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationSGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life
SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective
More informationSupplementary Online Content
Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationClinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene
Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Emily S. Wan, John E. Hokanson, James R. Murphy, Elizabeth A. Regan, Barry J. Make, David A. Lynch, James D. Crapo, Edwin K.
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationIs there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions?
Respiratory Medicine (2004) 98, 178 183 Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions? Maria Tsoumakidou, Nikolaos Tzanakis,
More informationClinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study
ORIGINAL ARTICLE COPD Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study Masaru Suzuki 1, Hironi Makita 1, Yoichi M. Ito 2, Katsura Nagai 1, Satoshi Konno 1 and Masaharu
More informationThe impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease
The impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease Dr. Lo Iek Long Department of Respiratory Medicine C.H.C.S.J. Chronic Obstructive Pulmonary Disease (COPD)
More informationThe Journal Club: COPD Exacerbations
252 The Journal Club: COPD Exacerbations Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club The Journal Club: COPD Exacerbations Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations:
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationManagement of Acute Exacerbations of COPD
MiCMRC Educational Webinar Management of Acute Exacerbations of COPD August 22, 2018 MiCMRC Educational Webinar Management of Acute Exacerbations of COPD Expert Presenter: Catherine A. Meldrum PhD RN MS
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationroflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationResearch in Real Life
Research in Real Life Study 1: Exploratory study - identifying the benefits of pmdi versus Diskus for delivering fluticasone/salmeterol combination therapy in patients with chronic obstructive pulmonary
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationUNDERSTANDING COPD MEDIA BACKGROUNDER
UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the
More informationClinical determinants of exacerbations in severe, early-onset COPD
Eur Respir J 2007; 30: 1124 1130 DOI: 10.1183/09031936.00009307 CopyrightßERS Journals Ltd 2007 Clinical determinants of exacerbations in severe, early-onset COPD M.G. Foreman*, D.L. DeMeo*,#, C.P. Hersh*,#,
More informationSydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK. Affiliated with
Sydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK Affiliated with COPD and Comorbidities Norbert Berend Professor Emeritus University of Sydney Head, Respiratory Research The George Institute
More informationOptimum treatment for chronic obstructive pulmonary disease exacerbation prevention
Commentary Page 1 of 5 Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention Pradeep Karur, Dave Singh Centre for Respiratory Medicine and Allergy, Medicines Evaluation Unit,
More informationTitle: Real-life use of inhaled corticosteroids in COPD patients vs. GOLD proposals: a paradigm shift in GOLD 2011?
ERJ Express. Published on October 31, 2013 as doi: 10.1183/09031936.00162313 Letter to the Editor Title: Real-life use of inhaled corticosteroids in COPD patients vs. GOLD proposals: a paradigm shift in
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationAsthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 19 February 2009 Doc. Ref. EMEA/CHMP/EWP/8197/2009 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CONCEPT
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationThe distribution of COPD in UK general practice using the new GOLD classification
ORIGINAL ARTICLE COPD The distribution of COPD in UK general practice using the new GOLD classification John Haughney 1, Kevin Gruffydd-Jones 2, June Roberts 3, Amanda J. Lee 4, Alison Hardwell 5 and Lorcan
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationC hronic obstructive pulmonary disease (COPD) is one of
589 RESPIRATORY INFECTIONS Time course of recovery of health status following an infective exacerbation of chronic bronchitis S Spencer, P W Jones for the GLOBE Study Group... Thorax 2003;58:589 593 See
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationRe-Submission. roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd. Published 11 September
Re-Submission roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd 4 August 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More informationChronic obstructive pulmonary disease (COPD) is characterized
RESEARCH Impact of COPD Exacerbation Frequency on Costs for a Managed Care Population Anand A. Dalal, PhD, MBA; Jeetvan Patel, MS; Anna D Souza, BPharm, PhD; Eileen Farrelly, MPH; Saurabh Nagar, MS; and
More informationE. Prescott + **, P. Lange* +, J. Vestbo**
Eur Respir J, 1995, 8, 1333 1338 DOI: 10.1183/09031936.95.08081333 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Chronic mucus hypersecretion
More informationReport of the American Thoracic Society International Conference 2010 Conference Report Sponsored by
Report of the American Thoracic Society International Conference 2010 Conference Report Sponsored by 1 Report of the American Thoracic Society International Conference 2010 CONTENTS What should we treat?
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationCirculating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study
ORIGINAL ARTICLE COPD Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study Yochai Adir 1, Omar Hakrush 1, Michal Shteinberg 1, Sonia Schneer 1 and Alvar Agusti
More informationReport of the COPD7 Conference Conference Report Sponsored by
Report of the COPD7 Conference 2010 Conference Report Sponsored by Report of the COPD7 Conference 2010 CONTENTS Burden of COPD Pages 3-4 Current challenges in COPD management Pages 5-6 Overcoming challenges
More informationResearch Review. Salmeterol/fluticasone propionate (Seretide ) in COPD. Extended listing for salmeterol/fluticasone propionate in COPD
Research Review Salmeterol/fluticasone propionate (Seretide ) in COPD Extended listing for salmeterol/fluticasone propionate in COPD In New Zealand, salmeterol/fluticasone propionate (SFC) (Seretide )
More informationThe Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia.
The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. Rennard, Stephen I; Sin, Donald D; Tashkin, Donald P; Calverley, Peter M; Radner, Finn Published in: Annals
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationAdvancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
Advancing COPD treatment strategies with evidencebased approaches 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy Increasing understanding of COPD and the effect on guideline evolution. GOLD
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease Catherine Whittaker (BPharm, MRPharmS) Abstract Chronic Obstructive Pulmonary Disease affects millions of people, has a major impact on quality of life and has become
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationFrancesco Blasi Head Respiratory Medicine Section Cardio-Thoracic Department University of Milan, Italy
COPD EXACERBATIONS Francesco Blasi Head Respiratory Medicine Section Cardio-Thoracic Department University of Milan, Italy COPD OUTCOMES Cazzola M et al. ERJ 2008 COPD AND CARDIOVASCULAR DISEASE Cumulative
More informationThis is the publisher s version. This version is defined in the NISO recommended practice RP
Journal Article Version This is the publisher s version. This version is defined in the NISO recommended practice RP-8-2008 http://www.niso.org/publications/rp/ Suggested Reference Chong, J., Karner, C.,
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationCOPD or not COPD, that is the question.
COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP
More informationC hronic obstructive pulmonary disease (COPD) is one of
935 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Developing COPD: a 25 year follow up study of the general population A Løkke, P Lange, H Scharling, P Fabricius, J Vestbo... See end of article for authors affiliations...
More informationTreatment of COPD: the sooner the better?
1 Respiratory Division, University of Leuven, Belgium 2 Respiratory Division, David Geffen School of Medicine, University of California, Los Angeles, USA Correspondence to Marc Decramer, Respiratory Division,
More informationexacerbation has greater impact on functional status than frequency of exacerbation episodes.
Original Article Singapore Med J 2011, 52(12) 894 Changes in the BODE index, exacerbation duration and hospitalisation in a cohort of COPD patients Bu X N, Yang T, Thompson M A, Hutchinson A F, Irving
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationShaping a Dynamic Future in Respiratory Practice. #DFResp
Shaping a Dynamic Future in Respiratory Practice #DFResp www.dynamicfuture.co.uk Inhaled Therapy in COPD: Past, Present and Future Richard Russell Chest Physician West Hampshire Integrated Respiratory
More informationCOPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases
COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases «If you test one smoker with cough every day You will diagnose
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationCOPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK
COPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK Presenter Disclosures Wisia Wedzicha All disclosures prior
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationJournal of the COPD Foundation. Journal Club. Chronic Obstructive Pulmonary Diseases:
85 Journal Club Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations: inhaled corticosteroid, ICS; long acting β 2 -agonist,
More informationChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease Abstract Whittaker C, BPharm, MRPharmS Amayeza Info Centre Chronic obstructive pulmonary disease affects millions of people, has a major impact on quality of life
More informationRoflumilast for the management of severe chronic obstructive pulmonary disease
Roflumilast for the management of severe chronic obstructive pulmonary disease Issued: January 2012 guidance.nice.org.uk/ta244 NICE has accredited the process used by the Centre for Health Technology Evaluation
More informationThe distribution of COPD in UK general practice using the new GOLD classification
ERJ Express. Published on October 31, 2013 as doi: 10.1183/09031936.00065013 The distribution of COPD in UK general practice using the new GOLD classification John Haughney 1, Kevin Gruffydd-Jones 2, June
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationA Validation Study for the Korean Version of Chronic Obstructive Pulmonary Disease Assessment Test (CAT)
http://dx.doi.org/10.4046/trd.2013.74.6.256 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2013;74:256-263 CopyrightC2013. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationStatistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited
Eur Respir J 28; 32: 17 24 DOI: 1.1183/931936.16157 CopyrightßERS Journals Ltd 28 PERSPECTIVE Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited O.N. Keene*, P.M.A. Calverley
More informationRoflumilast for the management of severe chronic obstructive pulmonary disease
Roflumilast for the management of severe chronic obstructive pulmonary disease Issued: January 2012 www.nice.org.uk/ta244 NHS Evidence has accredited the process used by the Centre for Health Technology
More informationStandardised mortality rates in females and males with COPD and asthma
Eur Respir J 2005; 25: 891 895 DOI: 10.1183/09031936.05.00099204 CopyrightßERS Journals Ltd 2005 Standardised mortality rates in females and males with COPD and asthma T. Ringbaek*, N. Seersholm # and
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationPredictive value of lung function below the normal range and respiratory symptoms for progression of chronic obstructive pulmonary disease
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Correspondence to: M Albers, Radboud University Nijmegen Medical Centre, Department of Primary Care [117-HAG], PO Box 9101, 6500 HB
More informationJournal of the COPD Foundation
132 Predictors of Change in SGRQ Score Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Original Research Baseline Severity as Predictor of Change in St George s Respiratory Questionnaire
More informationCenter for Respiratory and Sleep Medicine COPD Chronic Disease Management Program
Center for Respiratory and Sleep Medicine COPD Chronic Disease Management Program Cristina Ashworth, NP Khalil Diab,MD Center for Respiratory and Sleep Medicine Subgroup of Indiana Internal Medicine Consultants
More informationPeople with asthma who smoke. The combination of asthma, a chronic airway disease, and smoking increases the risk of COPD even more.
COPD Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, sputum (phlegm) production
More informationTHE PHARMA INNOVATION - JOURNAL Clinical Characteristics of Chronic Obstructive Pulmonary Disease
Received: 09012014 Accepted: 30032014 ISSN: 2277 7695 CODEN Code: PIHNBQ ZDBNumber: 26630382 IC Journal No: 7725 Vol. 3 No. 2. 2014 Online Available at www.thepharmajournal.com THE PHARMA INNOVATION JOURNAL
More informationDr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective
Dr Stephen Child General Physician Auckland 14:20-14:40 Secondary Care Perspective Wheeze Witchery Stephen Child MD, FRACP, FRCPC General Physician Respiratory Interest Director of Clinical Training Auckland
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationComparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification
ORIGINAL ARTICLE COPD Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification Paul W. Jones 1, Lukasz Adamek 2, Gilbert Nadeau 2 and Norbert Banik 3 Affiliations:
More informationDisclosures. Update on COPD & Asthma. Update on the Management of COPD. No Pharma Disclosures. NHLBI - Asthma Clinical Research Network
Update on COPD & Asthma Michael C. Peters, M.D. MAS Division of Pulmonary & Critical Care Medicine Cardiovascular Research Institute University of California San Francisco UCSF Primary Care Medicine San
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationCOPD UPDATE ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center
COPD UPDATE 2012 ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center Definition of COPD COPD is a preventable and treatable disease with some significant extra pulmonary effects that
More informationLong-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial
Eur Respir J 2010; 35: 287 294 DOI: 10.1183/09031936.00082909 CopyrightßERS Journals Ltd 2010 Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial D.P. Tashkin*, B. Celli
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More information